Cargando…

Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma—An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer

We describe an innovative approach for identification of tolerance breakage during immune checkpoint inhibitor therapy in malignant melanoma. Checkpoint inhibitor therapy enhances the immunologic clearance of cancer by suppressing pathways which induce immune suppression and tolerance. We posit that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wahl, Renate U., Leijs, Marike, Araujo, Arturo, Rübben, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139313/ https://www.ncbi.nlm.nih.gov/pubmed/32188047 http://dx.doi.org/10.3390/ijms21062020

Ejemplares similares

A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score
por: Schaefer, Hannah, et al.
Publicado: (2022)

Cutaneous Malignancies in Tattoos, a Case Series of Six Patients
por: Leijs, Marike, et al.
Publicado: (2021)

Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection
por: May, Marcella Ricardis, et al.
Publicado: (2022)

Cutaneous Basal Cell Carcinoma with Lymph Node and Pulmonary Metastases
por: Wahl, Renate U., et al.
Publicado: (2018)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
por: Issam Salah, Nour el Imane, et al.
Publicado: (2023)

Nondisjunction of a Single Chromosome Leads to Breakage and Activation of DNA Damage Checkpoint in G2
por: Quevedo, Oliver, et al.
Publicado: (2012)

Chromosome breakage after G2 checkpoint release
por: Deckbar, Dorothee, et al.
Publicado: (2007)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR
por: Rübben, Albert, et al.
Publicado: (2006)

Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
por: Angell, Trevor E., et al.
Publicado: (2017)

Cancer heterogeneity: converting a limitation into a source of biologic information
por: Rübben, Albert, et al.
Publicado: (2017)

Targeting immune checkpoints in malignant glioma
por: Zhang, Xuhao, et al.
Publicado: (2016)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

TNF-R1, an immune checkpoint in melanoma?
por: Bertrand, Florie, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

SAT-473 Thyroid Dysfunction in a Patient with Malignant Melanoma Treated with Immune Checkpoint Blockade
por: Gupta, Shaveta, et al.
Publicado: (2020)

Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition
por: Alharbi, Bandar, et al.
Publicado: (2023)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
por: Mazloom, Anita, et al.
Publicado: (2020)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
por: Safi, Mohammed, et al.
Publicado: (2022)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
por: Yu, Jing, et al.
Publicado: (2022)

Cellular immunity in human malignant melanoma and melanoma histology.
por: Cameron-Mowat, D. E., et al.
Publicado: (1973)

Bone breakage
por: Wells, William A.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_cm65frcbk6ah4m8s6np8ormoss